Beximco Pharma launches affordable generic cystic fibrosis drug Triko

Beximco Pharmaceuticals has launched an affordable generic version of one of the world's most effective treatments for cystic fibrosis (CF), a rare and life-threatening genetic disorder, in a move that could significantly improve access to treatment for patients globally.

The company formally handed over its drug, Triko, to cystic fibrosis patients and representatives from six countries, including the US, UK and South Africa, at an event held today (15 June) at its manufacturing facility in Tongi.

Representatives of the UK-based patient advocacy organisation Right to Breathe were also present at the ceremony.

According to Beximco Pharmaceuticals, Triko is a combination therapy of elexacaftor, tezacaftor and ivacaftor, and is the generic version of Trikafta, a breakthrough cystic fibrosis drug developed by Vertex Pharmaceuticals.

The company said the initiative will enable patients in many countries to access advanced therapy at a fraction of the prevailing global cost.

Cystic fibrosis is a rare inherited disease in which thick mucus builds up in the lungs and digestive system, causing serious breathing and digestive problems. Without treatment, it can greatly shorten life expectancy.

Globally, about 160,000 people are living with cystic fibrosis, while another 80,000 cases are estimated to be undiagnosed, mainly in low- and middle-income countries.

Beximco said the annual cost of Trikafta in the US is about $370,000 per patient, while Triko is priced at $12,750 for adults and $6,375 for children, making it roughly 96% cheaper than the original drug.

The company has also introduced Bexdeco, a generic version of ivacaftor, priced at $5 per tablet.

The treatment rollout was first announced at the North American Cystic Fibrosis Conference in Seattle last year, after advocacy by a coalition of parents of children with cystic fibrosis. Monday's event marked the implementation of that commitment.

Gail Pleasur, leader of the Right to Breathe global campaign and a patient rights advocate, said access to life-saving treatment is a fundamental human right.

"Yet the majority of cystic fibrosis patients around the world remain deprived of modern therapies due to their high cost. Beximco's initiative can play a significant role in addressing this gap," she said.

Rabbur Reza, chief operating officer of Beximco Pharma, said the company has long been working to address unmet medical needs.

"We are proud to make this treatment available at an affordable price for cystic fibrosis patients. We hope this initiative will contribute to improving the quality of life of thousands of patients across the world," he said.